These data suggest that the dose-response relationships for primaquine's asexual stage and hypnozoitocidal activities in-vivo are different.
Dr. Dondorp is the Deputy Director and Head of malaria research at the Mahidol-Oxford Research Unit in Bangkok, Thailand, where he plans, coordinates and supervises clinical and laboratory malaria studies.
Artemisinin combination therapies are the first-line treatments for uncomplicated Plasmodium falciparum malaria in most malaria-endemic countries. Recently, partial artemisinin-resistant P. falciparum malaria has emerged on the Cambodia–Thailand border.
In this study, we analysed the longevity of both antibody and B cell memory responses to malaria antigens among individuals who were living in an area of extremely low malaria transmission in northern Thailand, and who were known either to be malaria naïve or to have had a documented clinical attack of P. falciparum and/or P. vivax in the past 6 years.
The authors discuss the compliance associated with a three-day AS-MQ regimen following a recent change in the treatment guidelines for uncomplicated falciparum malaria in Thailand. The patient data are supported by whole blood/plasma drug levels. In malaria treatment compliance remains a major factor determining effectiveness.
We discuss the implications of our results for understanding prevalence patterns in long-term malaria datasets from Kenya that show multi-annual cycles and one from Thailand that does not and discuss the possible implications of treatment.
Apical membrane antigen-1 is a candidate for inclusion in a vaccine for the human malaria parasite Plasmodium vivax.
Interferon-γ (IFN-γ) has been suggested to play an important role in the pathogenesis of malaria.
A haplotype block in which a primary polymorphism associated with severe malaria is likely to be encoded was identified in Thai malaria patients.